Lobeglitazone, a Novel Peroxisome Proliferator-Activated Receptor γ Agonist, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice.

Kwi Hyun BaeJung Beom SeoYun A JungHye Young SeoSun Hee KangHui Jeon JeonJae Man LeeSungwoo LeeJung Guk KimIn Kyu LeeGwon Soo JungKeun Gyu Park

Published in: Endocrinology and metabolism (Seoul, Korea) (2017)

The present study demonstrates that lobeglitazone has a protective effect on UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of non-diabetic origin renal disease.

Keyphrases

type diabetes
high glucose
metabolic syndrome
adipose tissue
skeletal muscle
liver fibrosis
endothelial cells
high fat diet induced
replacement therapy
drug induced